Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Why Pulse Biosciences Stock Popped Today

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE

Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE

Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences Q2 Earnings Call Highlights

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026